Editas Medicine (EDIT) and Its Competitors Critical Survey
by Jessica Moore · The Cerbat GemEditas Medicine (NASDAQ:EDIT – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Editas Medicine to similar companies based on the strength of its valuation, analyst recommendations, profitability, risk, institutional ownership, dividends and earnings.
Insider & Institutional Ownership
71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Editas Medicine has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Editas Medicine’s rivals have a beta of 1.11, meaning that their average stock price is 11% more volatile than the S&P 500.
Earnings & Valuation
This table compares Editas Medicine and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Editas Medicine | $40.52 million | -$160.06 million | -3.43 |
| Editas Medicine Competitors | $734.33 million | $13.62 million | -10.01 |
Editas Medicine’s rivals have higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Editas Medicine and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Editas Medicine | -157.32% | -196.63% | -38.17% |
| Editas Medicine Competitors | -9,054.47% | -198.89% | -30.64% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Editas Medicine and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Editas Medicine | 1 | 0 | 6 | 0 | 2.71 |
| Editas Medicine Competitors | 9782 | 15047 | 45279 | 1571 | 2.54 |
Editas Medicine presently has a consensus target price of $5.83, suggesting a potential upside of 126.98%. As a group, “Biotechnology” companies have a potential upside of 99.67%. Given Editas Medicine’s stronger consensus rating and higher probable upside, research analysts clearly believe Editas Medicine is more favorable than its rivals.
Summary
Editas Medicine beats its rivals on 7 of the 12 factors compared.
Editas Medicine Company Profile
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.